Activation, EGFR leads to Increase, goblet cell number

• Rats who underwent small bowel resection had significantly more goblet cells (number of cells/mm villus/crypt in the ileum compared with sham operated animals. The rats that were treated with an EGFR inhibitor, ZD1839 50 mg/kg per day) starting at the day of surgery did not show the increase in goblet cells following small bowel resection (Jarboe et al, 2005). 

• The removal of EGF (human recombinant, 0.5 ng/ml) from the culture medium of human bronchial epithelial cells during differentiation in ALI reduced the number of goblet cells to 6.7 ± 0.8% from 15.5 ± 1.5 in cultures differentiated in the presence of EGF (Atherton et al, 2003). 

• A 30-min treatment of primary human bronchial epithelial cells at the air-liquid interface with 0.6 mM xanthine and 0.5 units xanthine oxidase resulted in a 2-fold increase in EGFR phosphorylation. Daily 30-min treatments of primary human bronchial epithelial cells at the air-liquid interface with 0.6 mM xanthine and 0.5 units xanthine oxidase for 3 days resulted in goblet cell metaplasia as evidenced by an increase in the numbers of MUC5AC-positive cells from 3.3 ± 1.2% to 21.6 ± 3.4%, a decrease in ciliated cell numbers, and increased MUC5AC protein expression (32.5 + 9.3% above PBS control). This effect could be inhibited by EGFR blockade with neutralizing antibodies (Casalino-Matsuda et al., 2006). 

• ALI cultures from bronchial epithelial cells of asthmatic children supplemented with 10ng/ml EGF showed a higher percentage of goblet cells (mean 23.4%) compared with cultures without EGF (mean 13.9%). Treatment of the EGF-supplemented cultures simultaneously with 0.2μg/ml or 2μg/ml AG147 resulted in decrease in the percentage of goblet cells (mean 13.1% and 7.7%, respectively) compared with cultures supplemented with EGF alone (Parker et al., 2015). 

• Treatment of mouse gut in organ culture, which do not have goblet cells at day 6, with 10 ng/mL EGF increased the colonic goblet cell index (number of goblet cells/total colonic epithelial cells) by 1.8-fold compared with untreated cultures (Duh et al., 2000). 

• The OVA-induced goblet cell hyperplasia (~33 mm2/mm) was significantly attenuated by 50 mg/kg gefitinib treatment for 12 h each day during days 14–20 (~12 mm2/mm, as measured by goblet cell area / perimeter of the bronchial basement membrane (Song et al., 2016). 

• Cigarette smoke exposure at 8 cigarettes (nonfiltered cigarettes; 1.2 mg nicotine, 12 mg condensate) per day for 5 days markedly increased AB/PAS staining in airway epithelia of male Sprague-Dawley rats and goblet cell numbers from 40 ± 19 to 167 ± 19 cells/mm of epithelium, while decreasing the number of ciliated cells (not quantified). Treatment with the EGFR inhibitor BIBX1522 during exposure dose-dependently decreased goblet cell numbers, with a maximal decrease seen for 3 mg/kg inhibitor (51 ± 19 cells/mm epithelium) (Takeyama et al., 2001b). 

• Intranasal instillation of 0.1 mg LPS (E.coli 0111:B4) once a day for 3 consecutive days induced increased number of goblet cells in the nasal epithelium (as judged by histopathology), with an approx. 50% increase in AB/PAS-stained epithelium compared to untreated controls. Intranasal instillation of EGFR inhibitor AG1478 1 hr after LPS instillation dose-dependently decreased the % AB/PAS-stained epithelium, with a maximal decrease seen at 10 mg/kg (Takezawa et al., 2016). 

• Sensitization of rats with 10 mg ovalbumin (OVA) intraperitoneally (i.p.) on days 0 and 10 followed by intratracheal OVA instillations (0.1%, 100 ml) on days 20, 22, and 24 significantly increased the numbers of goblet cells in the airway epithelium on day 26. OVA sensitized rats were also treated with i.p. administration (10 mg/kg 1 h before the intratracheal instillation of ovalbumin), intratracheal instillation (1025M, 100 ml on days 20, 22 and 24), and i.p. injection (10 mg/kg of every 24 h until the day before the rats were euthanized) of BIBX1522. This treatment with the EGFR inhibitor reduced the Alcian blue/PAS stained area from ~18% to ~4 % (Takeyama et al., 1999). 

• Treatment of human primary bronchial epithelial cells with 1 ng/mL amphiregulin or HB-EGF for 24 h significantly induced goblet cell differentiation in NHBE cells cultured in ALI demonstrated by CLCA1 (marker of goblet cells) expression (Hirota et al., 2012). 

• Stimulation of human bronchial epithelial cells with human bronchial epithelial growth factor (20 ng/mL) for 24 h, resulted in a remarkable increase in the number of cells expressing MUC5AC. Treatment of the house dust mite-induced asthma mouse model with Erlotinib (during day 14–day 23)-resulted in decreased MUC5AC density in the lung (Jia et al., 2021). 

• 105 PFUs of Sendai virus was intranasally administered to mice to reach maximal viral tissue levels at 3–5 days after inoculation and viral clearance by day 12. The blocking of EGFR by oral administration of 20 mg/kg EKB-569 daily during postinfection days 10–21 decreased the number of Muc5AC positive cells to ~2 compared with ~7 (cells/mm basement membrane) in lungs of virus only infected mice (Tyner et al., 2006).  

• Instillation of agarose plugs (0.7-0.8 mm diameter, 4% agarose II) in Fischer rats caused a time-dependent increase in goblet cell area (by AB/PAS staining), which was detectable as early as 24 h and was greatest 72 h post-instillation. The AB/PAS-stained area increased from 0.1 ± 0.1% in control animals to 4.7 ± 1.4, 13.3 ± 0.7, and to 19.1 ± 0.7% at 24, 48, and 72 h post-instillation, respectively. Goblet cell numbers increased from 0 to 13.1 ± 5.6, 25.7 ± 15.0, and 51.5 ± 9.0 cells/mm basal lamina at 24, 48, and 72 h post-instillation, respectively. Concurrently, the numbers of basal, ciliated, and secretory cells decreased. Treatment of the animals prior and after instillation with 80 mg/kg/day BIBX1522 resulted in a marked decrease in the AB/PAS-stained area (<5% at 72 h). Of note, the AB/PAS staining in the airway epithelia coincided with EGFR staining (Lee et al., 2000).

The following studies show that EGFR activation (upstream KE) occurs earlier than the increase of goblet cell (downstream KE), complying with temporal concordance terms of upstream KE occurring before downstream KE. 

• EGFR phosphorylation was detected in histamine stimulated NHBE cells in 2 hours and goblet cell differentiation marker CLCA1 mRNA was increased 5 days after histamine treatment (Hirota et al., 2012). 

• Treatment of rat conjunctival goblet cells with 0.1 µM EGF significantly increased phosphorylation of the EGFR by 28.6 ± 7.6- and 29.2 ± 3.2-fold at 1 and 5 minutes, respectively. At the same concentration, 24-hour EGF treatment increased proliferation 4.9 ± 1.8-fold. Similar observations were made with human conjunctival goblet cells: Treatment with 0.1 µM EGF significantly increased proliferation 1.5 ± 0.3-fold above basal (Li et al., 2013). In another study in rat conjunctival goblet cells, treatment with 0.1 µM EGF, TGF-α, or HB-EGF for 5 min significantly stimulated the phosphorylation of EGFR by 21.1 ± 2.5, 22.2 ± 6.7, and 19.9 ± 6.0 fold above basal level, and 24-h treatment stimulated cell proliferation 1.3 ± 0.1 fold, 1.2 ± 0.02 fold, and 1.1 ± 0.04 fold compared to untreated cells (WST-1 assay). These latter results were also confirmed by Ki-67 immunofluorescent staining, showing increases in positive cells by 61.4%, 38.1%, 27.8% following EGF, TGF-α, and HB-EGF treatment compared to untreated cells (Gu et al., 2008). 

• EGFR phosphorylation was observed in cultured rat conjunctival goblet cells after incubation with EGF for 1 or 5 minutes, and increase in number of goblet cells was measured at 24 hours after incubation with EGF for 20 minutes (Shatos et al., 2008).